Monitor for future insider transactions, especially exercise of warrants by Gilboa, which could signal confidence ahead of NS002 Pivotal Study results. High founder ownership may indicate alignment with shareholders but also concentration risk.
Price Chart
Executive Summary
Nasus Pharma Ltd insiders filed Form 3s disclosing ownership of securities, including options and warrants. Founder & Executive Chairman Udi Gilboa holds 1,919,281 ordinary shares and 17,970 warrants exercisable at $6.53. Two other insiders, Shacham Sharon and David Silberman, each hold options for 10,000 shares at $5.38. Dr. Dalia Megiddo, a founder and CDO, is deemed to beneficially own 1,888,873 shares through Formulex Pharma Innovations Ltd.
Key Facts
- Founder & Executive Chairman Udi Gilboa beneficially owns 1,919,281 ordinary shares and holds 17,970 warrants exercisable at $6.53 per share, expiring upon earlier of two years from issuance or 30 trading days after top-line results of NS002 Pivotal Study.
- Shacham Sharon and David Silberman each hold options for 10,000 ordinary shares at $5.38, granted December 11, 2025, with 625 vested as of March 18, 2026.
- Dr. Dalia Megiddo, Chief Development Officer and founder, is deemed to beneficially own 1,888,873 shares through Formulex Pharma Innovations Ltd.
- All filings are initial beneficial ownership disclosures under Section 16, likely related to new director or officer status.
Financial Impact
No direct financial impact disclosed; ownership structure shows concentration among founders. Warrants held by Gilboa represent potential future dilution of ~0.9% of current market cap if fully exercised.
Risk Factors
- Concentration of ownership among insiders may limit public float and increase volatility.
- Warrants expire based on timing of clinical trial results, introducing uncertainty around potential share issuance.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 12 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 3 Filing (NSRX) — Batch item 1 | 0001493152-26-013387 |
| Document: 0001493152-26-013387-index.html | 0001493152-26-013383 |
| Document: 0001493152-26-013387.txt | 0001493152-26-013386 |
| 3 Filing (NSRX) — Batch item 4 | 0001493152-26-013383 |
| Document: 0001493152-26-013383-index.html | 0001493152-26-013387 |
| Document: 0001493152-26-013383.txt | 0001493152-26-013387 |
| 3 Filing (NSRX) — Batch item 7 | 0001493152-26-013386 |
| Document: 0001493152-26-013386-index.html | 0001493152-26-013387 |
| Document: 0001493152-26-013386.txt | 0001493152-26-013387 |
| 3 Filing (NSRX) — Batch item 10 | 0001493152-26-013388 |
| Document: 0001493152-26-013388-index.html | 0001493152-26-013387 |
| Document: 0001493152-26-013388.txt | 0001493152-26-013387 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 8, 2026 18d ago | 6-K | $3.51 | awaiting T+20 | — | $3.49 (−0.57%) |
Sep 23, 2026 4w ago | 3 | $3.64 $3.06 | ▼ −15.93% | ▼ −16.62% | $3.49 (−4.12%) |
Sep 18, 2026 5w ago | 424B5 | $3.44 $3.21 | ▲ +6.83% | ▲ +5.92% | $3.49 (−1.45%) |
Sep 14, 2026 6w ago | 6-K | $3.65 $3.32 | ▼ −9.04% | ▼ −11.30% | $3.49 (−4.38%) |
Sep 14, 2026 6w ago | EFFECT | $3.65 $3.32 | ▼ −9.04% | ▼ −11.30% | $3.49 (−4.38%) |
Aug 21, 2026 9w ago | EFFECT | $4.00 $3.44 | ▼ −14.00% | ▼ −13.47% | $3.49 (−12.75%) |
Aug 19, 2026 9w ago | 6-K | $3.84 $3.53 | ▼ −8.07% | ▼ −6.12% | $3.49 (−9.11%) |
Aug 17, 2026 10w ago | 6-K | $3.70 $3.59 | ▼ −2.97% | ▼ −1.00% | $3.49 (−5.68%) |
Aug 17, 2026 10w ago | Press Release | $3.70 $3.59 | ▼ −2.97% | ▼ −1.00% | $3.49 (−5.68%) |
Apr 1, 2026 29w ago | EFFECT | $2.55 $2.56 | ▼ −0.39% | ▲ +9.33% | $3.49 (−36.86%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers